(Reuters) ? Delcath Systems Inc said its experimental cancer treatment was not effective in patients with colorectal cancer in a mid-stage trial, sending its shares down 12 percent in pre-market trade.
The setback comes a week after the same treatment method showed strong efficacy in treating primary liver cancer patients.
The company is designing a minimally invasive procedure to administer high dose chemotherapy drugs to only the diseased organs or regions of the body ? thereby restricting the harsh effects of chemo drugs on other body organs.
Wedbush Securities analyst Nieren Garten said Delcath, which already has a CE mark in Europe for the perfusion of the liver with melphalan, should not read too much into it.
?I think it would not be surprising that with a heavily pre-treated population of only 16 patients, you don?t get a response,? Garten said.
Delcath?s new drug application of the treatment was based on its other late-stage trial data of melanoma metastases and did not include this extra study, he said.
Delcath said its chemosaturation system, which was using melphalan for the treatment, did not prove to be efficacious as the patients had been heavily pre-treated with numerous other chemotherapies.
Sixteen patients with very late-stage colorectal cancer, which had spread
Read More from the Article Source: http://us.rd.yahoo.com/dailynews/rss/health/*http%3A//news.yahoo.com/s/nm/20110901/hl_nm/us_delcath
Source: http://www.rocketnews.com/2011/09/delcath-says-colorectal-cancer-treatment-not-effective-reuters/
continental bbq car dealerships big brother malls malls ridley scott
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.